FY25 revenue growth at 20%+ with 30%+ EBITDA margin. Doubling revenue to Rs 1,000 cr during FY24-27 at a CAGR of 21%. . Maintaining EBITDA margin of 28-30% over the long term
Share this post
Supriya Lifescience: PAT growth of 57% …
Share this post
FY25 revenue growth at 20%+ with 30%+ EBITDA margin. Doubling revenue to Rs 1,000 cr during FY24-27 at a CAGR of 21%. . Maintaining EBITDA margin of 28-30% over the long term